{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Mots C",
    "short_name": "MOTS-c",
    "aliases": [
      "motsc"
    ],
    "classification": {
      "category": "investigational_human",
      "needs_prescription": false,
      "notes": "Classification describes what MOTS-c is and the general domain where it appears."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-18",
      "human_use_note": "This entry summarizes how the compound is discussed/used in the real world without endorsing use or providing instructions."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "unknown",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Risk rating is conservative and reflects known uncertainties, evidence limitations, and potential for non-obvious harms.",
      "risk_score": 5
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "What it is and why it is studied are summarized here in a conservative, evidence-bounded way.",
          "evidence_refs": [
            "E1",
            "E2",
            "E3",
            "E4",
            "E5"
          ]
        }
      ],
      "use_cases": [
        {
          "text": "These are the most common real-world reasons people look into this peptide, plus the context that tends to matter most (quality, expectations, and safety).",
          "title": "Use cases (real-world)"
        },
        {
          "text": "metabolic health curiosity (early-stage evidence)"
        },
        {
          "text": "exercise tolerance and recovery discussions (mixed, often overstated)"
        },
        {
          "text": "sometimes discussed for insulin sensitivity themes (uncertain outcomes)"
        }
      ],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "unit": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "min": null,
          "max": null,
          "frequency": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "duration": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": [
        {
          "text": "Interactions here are category flags — they’re meant to help you ask better questions and avoid obvious conflicts. They are not a dosing guide.",
          "title": "Interaction summary"
        },
        {
          "text": "Drug-class flags to review:"
        },
        {
          "text": "diabetes-glucose-lowering"
        },
        {
          "text": "If you’re on cardiovascular, anticoagulant/antiplatelet, serotonergic, or immunomodulating meds/supplements, treat uncertainty as a reason to slow down and verify with a clinician."
        }
      ],
      "current_outlook_bullets": [
        "studied are summarized here in a conservative, evidence-bounded way",
        "general recovery and resilience interest (anecdotal)",
        "common biohacker curiosity due to community reports",
        "interest in mechanisms suggested by early evidence",
        "used in goal-based stacking discussions (anecdotal)",
        "exploration in wellness communities despite evidence limits"
      ]
    },
    "evidence": [
      {
        "source_id": "E1",
        "source_type": "journal_article",
        "evidence_grade": "animal",
        "title": "A 16-amino-acid peptide named MOTS-c regulates insulin sensitivity and metabolic homeostasis",
        "year": 2015,
        "url": "https://pubmed.ncbi.nlm.nih.gov/25738459/",
        "notes": "Discovery/characterization (animal + cellular). Mechanism framing only.",
        "id": "E1"
      },
      {
        "source_id": "E2",
        "source_type": "journal_article",
        "evidence_grade": "animal",
        "title": "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis",
        "year": 2021,
        "url": "https://pubmed.ncbi.nlm.nih.gov/33473109/",
        "notes": "Animal study; does not establish human efficacy.",
        "id": "E2"
      },
      {
        "source_id": "E3",
        "source_type": "journal_article",
        "evidence_grade": "human_observational",
        "title": "Effect of aerobic and resistance exercise on the mitochondrial-derived peptide MOTS-c (human observational biomarker context)",
        "year": 2021,
        "url": "https://www.nature.com/articles/s41598-021-96419-z",
        "notes": "Human observational/biomarker context; not proof of clinical benefit.",
        "id": "E3"
      },
      {
        "source_id": "E4",
        "source_type": "review",
        "evidence_grade": "unknown",
        "title": "MOTS-c: A promising mitochondrial-derived peptide (review)",
        "year": 2023,
        "url": "https://pubmed.ncbi.nlm.nih.gov/36761202/",
        "notes": "Review synthesis; use for uncertainty boundaries.",
        "id": "E4"
      },
      {
        "source_id": "E5",
        "source_type": "review",
        "evidence_grade": "unknown",
        "title": "MOTS-c, the Most Recent Mitochondrial Derived Peptide (review)",
        "year": 2022,
        "url": "https://pubmed.ncbi.nlm.nih.gov/36233287/",
        "notes": "Review synthesis; not proof of efficacy.",
        "id": "E5"
      }
    ],
    "changelog": [
      {
        "date": "2026-01-18",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for MOTS-c",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      },
      {
        "date": "2026-01-18T19:39:10+00:00",
        "change_type": "content_update",
        "summary": "Added conservative evidence set and linked overview evidence_refs (no instructions).",
        "detail": "Inserted primary discovery paper, animal study, human observational context, and two reviews. Linked overview blocks to evidence IDs. No dosing/protocol language added.",
        "evidence_refs": [
          "E1",
          "E2",
          "E3",
          "E4",
          "E5"
        ]
      }
    ],
    "meta": {},
    "topics": {
      "primary": [
        "topic_longevity_aging",
        "topic_fat_loss_metabolism"
      ]
    },
    "slug": "mots-c"
  },
  "canonical_name": "Mots C",
  "interactions": {
    "drug_classes": [
      "diabetes-glucose-lowering"
    ],
    "supplement_classes": [],
    "peptides": []
  },
  "practical": {
    "bottom_line": "MOTS-c is discussed for metabolic health and exercise performance themes, often framed as “mitochondrial support.” Human evidence is limited, so expectations should be conservative.",
    "benefits": [
      "metabolic health curiosity (early-stage evidence)",
      "exercise tolerance and recovery discussions (mixed, often overstated)",
      "sometimes discussed for insulin sensitivity themes (uncertain outcomes)"
    ],
    "side_effects_common": [
      "headache",
      "nausea",
      "fatigue"
    ],
    "side_effects_serious": [
      "severe allergic reaction symptoms (hives, facial swelling, trouble breathing)",
      "chest pain, fainting, or severe shortness of breath"
    ],
    "who_should_be_cautious": [
      "people with diabetes or unstable blood sugar control",
      "people with significant cardiovascular disease",
      "pregnant or breastfeeding individuals",
      "adolescents (limited human evidence and endocrine/metabolic uncertainty)"
    ],
    "schema_version": "practical_block_v1"
  }
}
